Betalin Therapeutics is a preclinical stage company developing an innovative therapy for diabetes treatment. This game changing technology aims to replace insulin therapy for millions of patients worldwide.

Our Story

Betalin Therapeutics is developing an Engineered Micro Pancreas (EMP) to improve the quality of life for millions of people with diabetes.

Betalin Therapeutics licensed the novel EMP technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.

Based on promising in vitro results and preliminary in vivo results, Betalin Therapeutics has recently submitted a pre-pre-IND (Investigational New Drug) application to the Food and Drug Administration (FDA). Following the FDA's positive response, Betalin Therapeutics is now preparing the pre-IND meeting on its way towards IND submission.

Betalin Therapeutics is currently raising funding in order to further optimize the therapy in animal models, complete submission of the IND application to the FDA, and proceed to clinical trials. Betalin Therapeutics was recently awarded a competitive matching grant from the Office of the Chief Scientist, doubling the impact of investments made at this stage.




Company Management


Mr. Joshua (Shuki) Herchovici

Chairman & Founder

Experience: Over 20 years of experience in establishing private & public companies such as D Medical Industries (Nasdaq: DMED, TASE: DMDC) and Nextgen (TASE: NXGN)


Dr. Nikolai Kunicher PhD, MBA


Over 10 years of experience in Biotech R&D management for companies such as, ARTSaVIT and AVA Biodefender. Served as Scientific Manager and Head of Business Development at Surgical Innovation and Technology Center, Hadassah Medical Center. Vast experience in Biotech R&D Management, with the ability to achieve the desired goals of the organization under strict timetable. Extensive experience in all of the development stages of Biotech product. Deep understanding of the Biotech industry from scientific and business points of view. Extensive knowledge of the IP management and patent submission.


Mr. Omer Glass

VP Business Development & Strategy, Betalin USA-omer@betalintherapeutics.com

Over 10 years of experience in business development & strategy, developing new businesses for leading global companies from Israel, US, UK, Singapore, Germany & Turkey.Led dozens of projects as a management consultant in Shaldor (top tier Israeli management consulting boutique), as a General Manager leading the establishment of new business units in leading companies and as an entrepreneur.Extensive experience in the healthcare industry, working with healthcare regulators, HMOs and developing new offerings for end customers.


Yonatan Ben Shimon

VP Marketing & PR, Betalin USA -yonatan@betalintherapeutics.com

Mr. Ben Shimon is a serial Entrepreneur, crypto builder, investor and the CEO and co-founder of Matchpool, a social and community-driven company that builds products using blockchain technology. He is also an advisor for the team building Beam, a scalable, confidential cryptocurrency that offers to be an anonymous store of value.


Dr. Avi Treves

VP Research & Development

Wide experience in translational research and clinical development, regenerative medicine and cells technologies, immuno-oncology, technology and business development of biotech companies, commercialization of hospitals and academic institutes programs. Dr. Treves is co-author of more than 100 scientific publications and 10 patents, and an active advisor in several biotech programs and companies. Dr. Treves was the founder and CEO of Hadasit Ltd. and Gamida-Cell Ltd. He obtained his Ph.D. from the Weizmann Institute of Science and post doc at Stanford University Medical School.


Dr. Orit Goldman

Senior Scientist and lab manager

Has 16 years of both scientific and clinical research, having worked in several top research institutes in three countries. Orit is an expert in stem cell research, both fundamental and clinical, human and mouse embryology, molecular and cell biology, biochemistry, imaging, as well as translational and oncological research. She did her Ph.D at Paul Brousse Hospital in Paris and her post-doc at Mount Sinai Hospital in New York. Since joining Betalin Therapeutics as senior scientist in May 2016, Orit has managed Betalin’s research project and lab.


Dr. Manuela Vecsler

Senior Scientist

has experience in management of pre-clinical and clinical research in genomics, molecular biology, biochemistry, neurology, immunology and cancer. Manuela did a post-doc in cell biology, specifically cell proliferation and growth at Bar Ilan University, her PhD in molecular genetics and biochemistry at Tel Aviv University. She is a Co-author of more than 20 publications including research articles and congress presentations.


Mr. Shay Herchovici, MBA

Head of Business Development Investment Strategist with BA and MBA in Business Management, manages the company’s investment strategy and supports its Business Development activities, actively pursuing the most attractive and synergetic funding opportunities.

Company Advisory Board


Prof. Arieh Warshel

Advisory Board Member

In chemistry (2013) for the development of multiscale models for complex chemical systems. Prof. Warshel is a pioneer in computational studies on functional properties of biological molecules. Distinguished Professor of Chemistry and Biochemistry at  University of Southern California in Los Angeles, USA, also worked in other renowned research institutes, such as Weizmann Institute of Science, Israel and the Laboratory of Molecular Biology at Cambridge, England.


Prof. Sidney Altman

Advisory Board Member

In chemistry for his discoveries concerning the catalytic properties of RNA. Sterling Professor of Molecular, Cellular, and Developmental Biology and Chemistry at Yale University, specializes in molecular biology, he worked in renowned universities such as Harvard, Yale and Cambridge


Prof. Eduardo Mitrani


Prof. Mitrani discovered and developed Betalin Therapeutics' core technology in his lab at The Hebrew University. Previous discoveries made and developed in Prof. Mitrani’s lab have been licensed by publicly traded companies including Ontogeny (Nasdaq: CRIS) and Medgenics (Nasdaq: MDGN). He has also been a visiting scholar at Harvard and Stanford Universities and publishes in prestigious journals including Cell, Science and Nature.


Prof. Camillo Ricordi

Scientific Advisory Board Member

Prof. Ricordi developed the Ricordi Method – an automated method for islet cell harvesting. He is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami Diabetes Research Institute. He has served as President of the Cell Transplant Society, Co-founder and Chairman of the National Diabetes Research Coalition, Co-founder and President of the International Association for Pancreas and Islet Transplantation and currently serves as the Director of the Diabetes Research Institute Cell Transplant Center and Responsible Head of the NIH-funded cGMP Human Cell Processing Facility.


Prof. James Shapiro

Scientific Advisory Board Member

Prof. Shapiro developed the Edmonton Protocol – the most advanced treatment currently being developed for the most severe cases of Type I diabetes. He is a professor of surgery, medicine and surgical oncology, and the director of the Clinical Islet Transplant Program at the University of Alberta in Edmonton, Canada and is the Canada Research Chair in Transplant Surgery and Regenerative Medicine.


Prof. Gil Leibowitz

Member of the Scientific Advisory Board

Senior Physician and specialist in the Endocrinology and Metabolism Unit, Hadassah Medical Center, Jerusalem, Israel. Chairman of the Diabetes Mellitus study center at the Hebrew University of Jerusalem


Today diabetes management requires a combination of medications and lifestyle changes. This is a physical, emotional and financial burden on millions of people with diabetes and their caregivers.


When we digest food, sugar is released into our blood. That sugar needs to be absorbed into the body and used for energy. Beta cells in the pancreas make and secrete insulin, which, in turn, allows the body to absorb glucose (sugar) from the blood. When beta cells malfunction, glucose is not absorbed from the blood in a steady, healthy fashion.
Diabetes is when the beta cells do not produce enough insulin, or when the body cannot use the insulin the beta cells produce.


TYPE I diabetes is when the body's own immune system attacks the cells, damaging them until they cannot do their job producing insulin. Type I diabetes is a chronic disease that requires life-long insulin supplement treatment and a strict lifestyle regimen to prevent complications like cardiovascular disease, damage to the eyes, kidneys and nerves, and premature death.
There is no cure.


TYPE II diabetes is when the beta cells do produce insulin but the body can't take advantage of it to get the job done. Type II diabetes is often caused by obesity, smoking and other unhealthy behaviors. More than 30% of people with Type II diabetes take insulin. Many are able to manage or even reverse their condition with lifestyle changes, sometimes combined with other medications that make it easier for their bodies to work with the insulin they do produce.

How many people are affected by diabetes

More than 420 million people worldwide suffer from diabetes1.

No one really knows why Type I diabetes develops, but it accounts for about 10% of cases worldwide* including more than 3 million Americans2.
80 more are diagnosed every day and that number goes up every year.

Diabetes management also takes a big toll – emotionally and financially – on loved ones and other caregivers of people with diabetes.

1 World Health Organization, 2014 2 Juvenile Diabetes Research Foundation


Betalin Therapeutics' EMPs are a technological breakthrough that has the potential to improve the lives of millions of people each year.

Betalin Therapeutics' proprietary technology is a biological micro-environment for supporting the harvested islets. The combination of the harvested cells and the proprietary micro-environment is called Engineered Micro-Pancreas (EMP).

Read More

The Science

"Islet transplantation has become a feasible cell therapy procedure that aims to achieve normoglycemia in severe diabetic patients. Currently, one of the greatest challenges in this approach is early islet cell death."



Betalin Therapeutics is developing an exciting new solution for diabetes treatment. Check out the latest news here.

Post Image
December, 2017

Betalin Therapeutics won the much coveted second prize of the Xi'an International Entrepreneurship Competition in China

Post Image
Horizon 2020 SME Instrument data hub, December 2017

Betalin received the H2020 prestigious award under the SME program

Post Image
Cision pr newswire, December 2017

Diabetes Research Institute Director Camillo Ricordi, M.D., Named a Fellow of National Academy of Inventors

Post Image
Globes.co.il, June 2017

Betalin Therapeutics wins best biopharma startup award

Post Image
Haaretz.com, June 2017

Israeli Startup Wants to Cure Diabetes by Making Micro-pancreases. It Worked on Mice

Post Image
Israelnationalnews.Com, June 2017

No more injections: Harvested cells act as pancreas

Post Image
Globes, December 2015

Israeli Startup aims to End Insulin Injections

Post Image
BusinessWire.com, November 2015

Betalin Therapeutics Introduces Novel Approach to Treat Diabetes

Post Image
Chengdu International Innovation & Entrepreneurship Competition on October 28

Chengdu International Innovation & Entrepreneurship Competition on October 28

Post Image
The 3rd China Beijing International Medical Engineering and International Medical Artificial

The 3rd China Beijing International Medical Engineering and International Medical Artificial

Post Image
Health Hub Vienna Batch #2

Health Hub Vienna Batch #2

Contact & Careers

Betalin Therapeutics is developing a cutting edge solution for diabetes. Contact us to find out how you can be a part of this exciting journey.

Betalin Therapeutics is currently in the pre-clinical phase and is not recruiting patients for clinical trials. If you are interested in participating in clinical trials in the future, watch this space for updates.

IBAN: IL38 0131 9000 0002 6120 033

+972 (50) 843 1473

+972 (50) 843 1473

Betalin’s Lab
+972 2 9922025
Jerusalem Bio Park (JBP) Minrav Bldg,
4th Floor Hadassah Ein Keren Campus Jerusalem,

Register to news alerts or Drop us a message

Error! Please enter your name.
Error! Please enter your valid E-mail ID.
Error! Please enter your message.
Error! Please enter your message.
Please send me news alerts
Success! Your message has been sent successfully.
Error! Sorry, error occured this time sending your message.

Other Inquiries


Betalin Therapeutics is a dynamic company with a strong vision in a growing global and local market. We constantly seek to grow our company with similarly highly-motivated, focused, and energetic individuals who wish to make a difference. We believe that Betalin Therapeutics is an ideal career opportunity for professionals who are seeking to expand their horizons and progress with an exciting company that is really going places. If you enjoy being committed to a challenging vision that will revolutionize diabetes treatment and if you're interested in advancing your career, you are welcome to send us your CV to: info@betalintherapeutics.com

Join Us!

Betalin Therapeutics has licensed an exciting, cutting edge technology with the potential to radically improve the lives of millions of patients worldwide. In order to take the next steps towards that aim, we are currently raising the capital that will allow us to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials. To hear more about how we can revolutionize diabetes treatment together, get in touch today.

Shai: +972 (77) 940 0370